▼ 0.72%
prev close
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Congressional Trades
2
All tracked trades
Members Trading
1
Unique members
Net Activity
-2
0 buys · 2 sells
Members Who Traded This Stock
2 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2025-10-31 | ROIVRoivant Sciences Ltd. - Common Shares | Sell | $1,001 - $15,000 | 132d ago | — | |
| 2025-10-30 | ROIVRoivant Sciences Ltd. - Common Shares | Sell | $1,001 - $15,000 | 132d ago | — |
2025-10-31
Lisa McClain
ROIV
Amount
$1,001 - $15,000
Filed
132d ago
2025-10-30
Lisa McClain
ROIV
Amount
$1,001 - $15,000
Filed
132d ago
Recent News
Powered by Polygon.io
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
9 Biotech Stocks Trading Far Below Fair Value With Up to 250% Upside Potential
Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars
Healthcare REIT Posts 16.4% NOI Growth as Shares Soar 93%: Why This Fund's New Stake Stands Out
Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025
Trade Timeline
Congressional activity, newest first
Lisa McClain
2025-10-31 · Sale
$1,001 - $15,000
Lisa McClain
2025-10-30 · Sale
$1,001 - $15,000